Lv52
1210 积分 2024-08-09 加入
A0851 Treatment outcomes of enfortumab vedotin plus pembrolizumab in lymph node–positive urothelial carcinoma patients fit for cystectomy: Real-world data from an enfortumab registry
1小时前
待确认
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
1个月前
已完结
Higher blood–brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography
1个月前
已关闭
Real world efficacy and safety of ivosidenib in US veterans with IDH1 mutated cholangiocarcinoma
4个月前
已完结
262MO Preliminary efficacy outcomes of ivosidenib in patients with IDH1-mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study
4个月前
已关闭
Final Results from a First-in-Human Phase 1 Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations
4个月前
已完结
An evaluation of zanidatamab, a novel, anti-HER2 biparatopic antibody, for the treatment of biliary tract cancer
4个月前
已完结
Efficacy and safety of targeted therapy and immune checkpoint inhibitors in patients with advanced or metastatic biliary tract cancer: a meta-analysis of and sequential analysis of trials
5个月前
已完结
Liquid Biopsy in CRC Management: Early Detection, Minimal Residual Disease, and Therapy Optimization—Clinical Evidence and Challenges
6个月前
已完结
皖公网安备34019202002308
